Nosopharm
Nosopharm is an innovative biotechnology company headquartered in Lyon (France) and specialized in the research and development of new molecules to combat antimicrobial resistance (AMR). The mission of Nosopharm is to discover and develop novel first-in-class anti-infectives addressing unmet medical needs. The innovative anti-infective drug discovery platform developed by Nosopharm is based on the therapeutic exploitation of a very original bioresource: the bacterial genera Xenorhabdus and Photorhabdus. The company is also part of a pan-European Project (the Gram-negative Antibacterial Engine) focusing on fighting superbugs, a major issue related to hospital-acquired infections.
Nosopharm is an innovative biotechnology company headquartered in Lyon (France) and specialized in the research and development of new molecules to combat antimicrobial resistance (AMR). The mission of Nosopharm is to discover and develop novel first-in-class anti-infectives addressing unmet medical needs. The innovative anti-infective drug discovery platform developed by Nosopharm is based on the therapeutic exploitation of a very original bioresource: the bacterial genera Xenorhabdus and Photorhabdus. The company is also part of a pan-European Project (the Gram-negative Antibacterial Engine) focusing on fighting superbugs, a major issue related to hospital-acquired infections.